Radioisotopes Research Today is a free monthly online journal that collates and summarizes the latest research about Radioisotopes, including details on radioimmunotherapy, radionuclides, procedures, hazards.

Preparation and characterization of a DOTA-lysine-biotin conjugate as an effector molecule for pretargeted radionuclide therapy.

Hainsworth J, Harrison P, Mather SJ

Cancer Research UK, Nuclear Medicine Group, St. Bartholomew's Hospital, London.

Pretargeted radionuclide therapy depends on the establishment of a high concentration of secondary binding sites at a tumor to which low-molecular weight radiolabeled effector molecules can be directed. This study describes the simple synthesis of an effector molecule and its subsequent characterization to determine the extent to which it complied with the ideal requirements of such a compound. (Epsilon)-DOTA-(alpha)-biotinamidolysine (DLB) was synthesized in high yield and purity using conventional SPPS methodology. High radiochemical purities were obtained when labeled with several potentially useful radionuclides. The radiolabeled analogue bound to streptavidin efficiently with a stoichiometry similar to that of native biotin and showed high stability in serum and upon challenge with acid conditions. Biodistribution studies in normal animals showed a rapid rate of clearance from the blood and low retention of radioactivity by normal tissues. This design of effector molecule therefore shows promise for further pretargeted radionuclide therapy studies.

Published 18 November 2005 in Bioconjug Chem, 16(6): 1468-74.
Full-text of this article is available online (may require subscription).

© 2005-2008 Radioisotopes Research Today. All Rights Reserved.